Protocol Ledger

NCT06284317 · Phase III · RECRUITING

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Interventional Phase III clinical trial protocol NCT06284317 sponsored by ETOP IBCSG Partners Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-15 Enrollment: 290 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06284317
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)290 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06284317
Protocol FieldVerified Registry Value
NCT IdentifierNCT06284317
Consolidated Lead SponsorETOP IBCSG Partners Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment290 participants (ESTIMATED)
Registered Start Date2025-01-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06284317
Hospital Research SiteLocationSite Profile
Chris O'Brien LifehouseCamperdown, AustraliaOpen Hospital Dossier ->
Royal North Shore HospitalSt Leonards, AustraliaOpen Hospital Dossier ->
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->
Flinders Medical CentreBedford Park, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI